成人H3 K27M突变型胶质瘤的特征
该研究分析了21例成人H3 K27M突变型胶质瘤,并与135例成人IDH/H3野生型弥漫性胶质瘤比较。H3 K27M突变型胶质瘤均位于中线,MGMT启动子甲基化率低,缺乏EGFR扩增,中位生存期19.6个月,与IDH/H3野生型胶质瘤的17个月无显著差异(P=0.3)。
要点
- 成人H3 K27M突变型胶质瘤均位于中线,IDH和BRAF-V600E均为野生型。
- H3 K27M突变型胶质瘤MGMT启动子甲基化率低(1/21 vs 52/129,P=0.002)。
- H3 K27M突变型胶质瘤中位生存期19.6个月,IDH/H3野生型为17个月(P=0.3)。
核心结论
- 在成人中,如同儿童,H3 K27M突变定义了IDH野生型胶质瘤的一个独特亚群,其特征为持续的中线位置、低MGMT启动子甲基化率和不良预后。
研究设计与样本
- 研究分析了21例成人H3 K27M突变型胶质瘤,并与135例成人IDH/H3野生型弥漫性胶质瘤进行比较。
主要发现
- H3 K27M突变型胶质瘤诊断时中位年龄32岁(范围18-82岁)。
- 所有肿瘤均位于中线(脊髓6例,丘脑5例,脑干5例,小脑3例,下丘脑1例,松果体区1例),且均为IDH和BRAF-V600E野生型。
- H3 K27M突变识别在3例(14%)初始组织学提示弥漫性低级别胶质瘤的患者中显著影响诊断,在7例(33%)病理分析难以在弥漫性胶质瘤、神经节胶质瘤或毛细胞星形细胞瘤之间确定的患者中显著影响诊断。
- 与IDH/H3野生型胶质瘤相比,H3 K27M突变型胶质瘤诊断年龄更早(32 vs 64岁,P < .001),均位于中线(21/21 vs 21/130,P < .001),MGMT启动子甲基化频率更低(1/21 vs 52/129,P = .002),且缺乏EGFR扩增(0/21 vs 26/128,P = .02)。
- H3 K27M突变型胶质瘤中位生存期19.6个月,IDH/H3野生型胶质瘤为17个月(P = .3)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diffuse H3 K27M-mutant gliomas occur primarily in children but can also be encountered in adults. The aim of this study was to describe the characteristics of H3 K27M-mutant gliomas in adults. METHODS: We analyzed the characteristics of 21 adult H3 K27M-mutant gliomas and compared them with those of 135 adult diffuse gliomas without histone H3 and without isocitrate dehydrogenase (IDH) mutation (IDH/H3 wild type). RESULTS: The median age at diagnosis in H3 K27M-mutant gliomas was 32 years (range: 18-82 y). All tumors had a midline location (spinal cord n = 6, thalamus n = 5, brainstem n = 5, cerebellum n = 3, hypothalamus n = 1, and pineal region n = 1) and were IDH and BRAF-V600E wild type. The identification of an H3 K27M mutation significantly impacted the diagnosis in 3 patients (14%) for whom the histological aspect initially suggested a diffuse low-grade glioma and in 7 patients (33%) for whom pathological analysis hesitated between a diffuse glioma, ganglioglioma, or pilocytic astrocytoma. Compared with IDH/H3 wild-type gliomas, H3 K27M-mutant gliomas were diagnosed at an earlier age (32 vs 64 y, P < .001), always had a midline location (21/21 vs 21/130, P < .001), less frequently had a methylated MGMT promoter (1/21 vs 52/129, P = .002), and lacked EGFR amplification (0/21 vs 26/128, P = .02). The median survival was 19.6 months in H3 K27M-mutant gliomas and 17 months in IDH/H3 wild-type gliomas (P = .3). CONCLUSION: In adults, as in children, H3 K27M mutations define a distinct subgroup of IDH wild-type gliomas characterized by a constant midline location, low rate of MGMT promoter methylation, and poor prognosis.
引用
- Meyronet D, Esteban-Mader M, Bonnet C, et al. Characteristics of H3 K27M-mutant gliomas in adults. Neuro Oncol. 2017. PMID: 28201752. doi:10.1093/neuonc/now274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。